Prevalence and Phenotype of Lower Urinary Tract Symptoms in Fibromyalgia: A Retrospective Observational Study at a Single Tertiary Medical Center
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Data Sources and Data Collection
2.3. Inclusion and Exclusion Criteria
- (a)
- Genitourinary birth defects of the kidney, ureter, or bladder;
- (b)
- Prior or current genitourinary malignancy;
- (c)
- A history of genitourinary surgery during the study period.
2.4. Collection of Relevant Variables
2.5. Statistical Analysis
3. Results
3.1. Notable Findings
3.2. Multivariate Analyses
3.3. Symptom Burden
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
BMI | Body Mass Index |
CAD | Coronary Artery Disease |
CI | Confidence Interval |
CPPS | Chronic Pelvic Pain Syndrome |
EMR | Electronic Medical Record |
FM | Fibromyalgia |
HLD | Hyperlipidemia |
HTN | Hypertension |
IBD | Inflammatory Bowel Disease |
IBS | Irritable Bowel Syndrome |
IC | Interstitial Cystitis |
IQR | Interquartile Range |
IRB | Institutional Review Board |
IRR | Incidence Rate Ratio |
LUTS | Lower Urinary Tract Symptoms |
MI | Mixed Incontinence |
OAB | Overactive Bladder |
OR | Odds Ratio |
PHI | Protected Health Information |
SD | Standard Deviation |
SUI | Stress Urinary Incontinence |
UI | Urinary Incontinence |
References
- Jones, G.T.; Atzeni, F.; Beasley, M.; Flüß, E.; Sarzi-Puttini, P.; Macfarlane, G.J. The prevalence of fibromyalgia in the general population: A comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015, 67, 568–575. [Google Scholar] [CrossRef]
- Plaut, S. “Long COVID-19” and viral “fibromyalgia-ness”: Suggesting a mechanistic role for fascial myofibroblasts (Nineveh, the shadow is in the fascia). Front. Med. 2023, 10, 952278. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kaltsas, G.; Tsiveriotis, K. Fibromyalgia. In Endotext; Feingold, K.R., Ahmed, S.F., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., et al., Eds.; Table 4. [2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria]; MDText.com, Inc.: South Dartmouth, MA, USA, 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK279092/table/fibromyalgia.T.2016_revisions_to_the_201/ (accessed on 10 July 2025).
- Gyorfi, M.; Rupp, A.; Abd-Elsayed, A. Fibromyalgia pathophysiology. Biomedicines 2022, 10, 3070. [Google Scholar] [CrossRef]
- Di Franco, M.; Iannuccelli, C.; Valesini, G. Neuroendocrine immunology of fibromyalgia. Ann. N. Y. Acad. Sci. 2010, 1193, 84–90. [Google Scholar] [CrossRef] [PubMed]
- Bradley, L.A. Pathophysiology of fibromyalgia. Am. J. Med. 2009, 122 (Suppl. S12), S22–S30. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Abrams, P. New words for old: Lower urinary tract symptoms for “prostatism”. BMJ 1994, 308, 929–930. [Google Scholar] [CrossRef]
- Esteban-Fuertes, M.; Prieto-Chaparro, L.; Arlandis-Guzmán, S.; Salinas-Casado, J.; Gago-Ramos, J.L.; Ifu, G. Is there concordance between overactive bladder and detrusor overactivity in men with predominant storage urinary symptoms referred to functional urology and urodynamics units? Actas Urológicas Españolas 2022, 46, 41–48. [Google Scholar] [CrossRef] [PubMed]
- Irwin, D.E.; Milsom, I.; Kopp, Z.; Abrams, P.; EPIC Study Group. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur. Urol. 2008, 53, 1029–1039. [Google Scholar] [CrossRef] [PubMed]
- Hughes, F.M., Jr.; Odom, M.R.; Cervantes, A.; Livingston, A.J.; Purves, J.T. Why Are Some People with Lower Urinary Tract Symptoms (LUTS) Depressed? New Evidence That Peripheral Inflammation in the Bladder Causes Central Inflammation and Mood Disorders. Int. J. Mol. Sci. 2023, 24, 2821. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Goldberg, N.; Tamam, S.; Weintraub, A.Y. The association between overactive bladder and fibromyalgia: A systematic review and meta-analysis. Int. J. Gynecol. Obstet. 2022, 159, 630–641. [Google Scholar] [CrossRef] [PubMed]
- Puri, B.K.; Lee, G.S. Overactive bladder symptoms in patients with fibromyalgia: A systematic case-controlled study. Rev. Recent Clin. Trials 2021, 16, 202–205. [Google Scholar] [CrossRef] [PubMed]
- Laden, B.F.; Bresee, C.; De Hoedt, A.; Dallas, K.B.; Scharfenberg, A.; Saxena, R.; Senechal, J.F.; Barbour, K.E.; Kim, J.; Freedland, S.J.; et al. Comorbidities in a nationwide, heterogenous population of veterans with interstitial cystitis/bladder pain syndrome. Urology 2021, 156, 37–43. [Google Scholar] [CrossRef] [PubMed]
- Dos Santos, G.B.; de Oliveira Sato, T.; Miwa-Cerqueira, T.; Bifani, B.E.; Rocha, A.P.R.; Carvalho, C. Pelvic floor dysfunctions in women with fibromyalgia: A cross-sectional study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2023, 282, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Martínez, L.A.; Mora, T.; Vargas, A.; Fuentes-Iniestra, M.; Martínez-Lavín, M. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: A review of case-control studies. J. Clin. Rheumatol. 2014, 20, 146–150. [Google Scholar] [CrossRef]
- Siracusa, R.; Di Paola, R.; Cuzzocrea, S.; Impellizzeri, D. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int. J. Mol. Sci. 2021, 22, 3891. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Lichtenstein, A.; Tiosano, S.; Amital, H. The complexities of fibromyalgia and its comorbidities. Curr. Opin. Rheumatol. 2018, 30, 94–100. [Google Scholar] [CrossRef] [PubMed]
- Cole, J.A.; Rothman, K.J.; Cabral, H.J.; Zhang, Y.; A Farraye, F. Migraine, fibromyalgia, and depression among people with IBS: A prevalence study. BMC Gastroenterol. 2006, 6, 26. [Google Scholar] [CrossRef] [PubMed]
- Nickel, J.C.; Tripp, D.A.; Pontari, M.; Moldwin, R.; Mayer, R.; Carr, L.K.; Doggweiler, R.; Yang, C.C.; Mishra, N.; Nordling, J. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J. Urol. 2010, 184, 1358–1363. [Google Scholar] [CrossRef]
- Lai, H.H.; Rawal, A.; Shen, B.; Kaufman, M.R.; Steers, W.D.; Theoharides, T.C. The relationship between anxiety and overactive bladder or urinary incontinence symptoms in the clinical population. Urology 2016, 98, 50–57. [Google Scholar] [CrossRef]
- Melotti, I.G.R.; Juliato, C.R.T.; Magna, L.A.; Ruffert, K.; Castro, R.A. Severe depression and anxiety in women with overactive bladder. Neurourol. Urodyn. 2018, 37, 223–228. [Google Scholar] [CrossRef]
- Pascart, T.; Carpentier, P.; Choi, H.K.; Norberciak, L.; Ducoulombier, V.; Luraschi, H.; Houvenagel, E.; Legrand, J.; Verclytte, S.; Becce, F.; et al. The prevalence of psychiatric and chronic pain comorbidities in fibromyalgia: An ACTTION systematic review and meta-analysis. Semin. Arthritis Rheum. 2021, 51, 895–902. [Google Scholar] [CrossRef]
- Patel, U.J.; Godecker, A.L.; Giles, D.L.; Brown, H.W. Updated prevalence of urinary incontinence in women: 2015–2018 national population-based survey data. Urogynecology 2022, 28, 181–187. [Google Scholar] [CrossRef]
- Mckellar, K.; Abraham, N. Prevalence, risk factors, and treatment for women with stress urinary incontinence in a racially and ethnically diverse population. Urodynamics 2019, 38, 934–940. [Google Scholar] [CrossRef]
- McKellar, K.; Foley, E.; Levy, G.; Abraham, N. Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population. Urology 2019, 126, 70–75. [Google Scholar] [CrossRef]
- Coyne, K.S.; Sexton, C.C.; Thompson, C.L.; Milsom, I.; Irwin, D.; Kopp, Z.S.; Chapple, C.R.; Kaplan, S.; Tubaro, A.; Aiyer, L.P.; et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: Results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009, 104, 352–360. [Google Scholar] [CrossRef]
- Smith, A.L.; Berry, A.; Brubaker, L.; Cunningham, S.D.; Gahagan, S.; Low, L.K.; Mueller, M.; Sutcliffe, S.; Williams, B.R.; Brady, S.S.; et al. The brain, gut, and bladder health nexus: A conceptual model linking stress and mental health disorders to overactive bladder in women. Neurourol. Urodyn. 2024, 43, 424–436. [Google Scholar] [CrossRef]
- Pan, T.; He, T.; Yuan, H.; Bai, X.; Sun, W.; Li, Y.; Zheng, Z.; Bai, P. Depression of any severity was associated with stress urinary incontinence in females: A retrospective study based on NHANES 2005–2018. Urology 2025, 198, 17–25. [Google Scholar] [CrossRef] [PubMed]
- Sanchez, R.; Uribe, C.; Li, H.; Alvir, J.; Deminski, M.; Chandran, A.; Palacio, A. Longitudinal evaluation of health care utilization and costs during the first three years after a new diagnosis of fibromyalgia. Curr. Med Res. Opin. 2011, 27, 663–671. [Google Scholar] [CrossRef] [PubMed]
- Hanno, P.M.; Landis, J.R.; Matthews-Cook, Y.; Kusek, J.; Nyberg, L.J., Jr. The diagnosis of interstitial cystitis revisited: Lessons learned from the National Institutes of Health Interstitial Cystitis Database Study. J. Urol. 1999, 161, 553–557. [Google Scholar] [CrossRef] [PubMed]
- Lamb, L.E.; Timar, R.; Wills, M.; Dhar, S.; Lucas, S.M.; Komnenov, D.; Chancellor, M.B.; Dhar, N. Long COVID and COVID-19-associated cystitis (CAC). Int. Urol. Nephrol. 2022, 54, 17–21. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Hastie, C.E.; Lowe, D.J.; McAuley, A.; Mills, N.L.; Winter, A.J.; Black, C.; Scott, J.T.; O’dOnnell, C.A.; Blane, D.N.; Browne, S.; et al. True prevalence of long-COVID in a nationwide, population cohort study. Nat. Commun. 2023, 14, 7892. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Subcategory | Value |
---|---|---|
Total Sample | - | n = 440 |
Age (years) | Mean ± SD | 51.8 ± 12.8 |
Median (IQR) | 52 (44–60) | |
Range | 21–87 | |
Sex | Female | 440 (100.0%) |
Race/Ethnicity | White | 207 (47.0%) |
Black/African Am | 199 (45.2%) | |
Hispanic/Latino | 12 (2.7%) | |
Mixed/Other | 10 (2.3%) | |
Unknown | 8 (1.8%) | |
Asian | 3 (0.7%) | |
Other | 1 (0.2%) | |
Age Groups | <40 years | 84 (19.1%) |
40–49 years | 109 (24.8%) | |
50–59 years | 140 (31.8%) | |
≥60 years | 107 (24.3%) | |
Comorbidity Burden | Mean ± SD | 2.87 ± 1.63 |
Median (IQR) | 3 (2–4) | |
Range | 0–7 |
Variable | Category/Measure | Percentage |
---|---|---|
LUTS Conditions | CPPS | 13.6% |
Stress Incontinence | 17% | |
Overflow Incontinence | 1.0% | |
Mixed Incontinence | 10.9% | |
Urge Incontinence | 15.2% | |
Interstitial Cystitis | 3.0% | |
Recurrent Cystitis | 6.4% | |
Overactive Bladder | 6.8% | |
Urinary Urgency | 2.5% | |
Urinary Frequency | 3.6% | |
Nocturia | 2.5% | |
Dysuria | 2.0% | |
Any LUTS Condition | 37.0% | |
Other Conditions | Obesity | 68.0% |
GAD | 34.7% | |
MDD | 42.3% |
Variable | Adjusted OR (95% CI) | p-Value |
---|---|---|
Age | 1.02 (1.00–1.04) | 0.1262 |
Asian | 0.00 (N/A) | 1.0000 |
Black | 0.69 (0.41–1.14) | 0.1472 |
Hispanic | 0.74 (0.16–3.40) | 0.6993 |
Mixed | 0.88 (0.17–4.71) | 0.8856 |
Other Race/Unknown | 1.34 (0.28–6.34) | 0.7125 |
Tobacco Use | 1.12 (0.66–1.91) | 0.6764 |
IBS | 8.53 (4.64–15.71) | <0.0001 |
HTN/HLD/CAD | 1.30 (0.76–2.24) | 0.3427 |
Obesity | 1.45 (0.82–2.54) | 0.1995 |
MDD | 1.57 (0.94–2.64) | 0.0855 |
GAD | 4.62 (2.74–7.77) | <0.0001 |
Variable | IRR (95% CI) | p-Value |
---|---|---|
Asian | 0.00 (0.00–inf) | 0.9991 |
Black | 0.92 (0.65–1.30) | 0.6410 |
Hispanic | 0.97 (0.33–2.88) | 0.9604 |
Mixed | 1.89 (0.76–4.69) | 0.1711 |
Other/Race Unknown | 2.56 (1.01–6.50) | 0.0479 |
Age | 1.01 (1.00–1.02) | 0.1688 |
Tobacco Use | 1.22 (0.86–1.72) | 0.2676 |
Other Autoimmune Disease | 1.27 (0.92–1.75) | 0.1415 |
IBS | 2.86 (2.03–4.04) | <0.0001 |
IBD | 1.92 (0.80–4.62) | 0.1449 |
HTN/HLD/CAD | 1.17 (0.81–1.69) | 0.4031 |
Obesity | 1.34 (0.91–1.98) | 0.1413 |
MDD | 1.24 (0.88–1.76) | 0.2188 |
GAD | 2.23 (1.57–3.15) | <0.0001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
McClain, J.; Capo, G.; Terris, M.; Santamaria, P.; Rolle, N.A. Prevalence and Phenotype of Lower Urinary Tract Symptoms in Fibromyalgia: A Retrospective Observational Study at a Single Tertiary Medical Center. J. Clin. Med. 2025, 14, 5584. https://doi.org/10.3390/jcm14155584
McClain J, Capo G, Terris M, Santamaria P, Rolle NA. Prevalence and Phenotype of Lower Urinary Tract Symptoms in Fibromyalgia: A Retrospective Observational Study at a Single Tertiary Medical Center. Journal of Clinical Medicine. 2025; 14(15):5584. https://doi.org/10.3390/jcm14155584
Chicago/Turabian StyleMcClain, Jackson, Gustavo Capo, Martha Terris, Pablo Santamaria, and Noelle A. Rolle. 2025. "Prevalence and Phenotype of Lower Urinary Tract Symptoms in Fibromyalgia: A Retrospective Observational Study at a Single Tertiary Medical Center" Journal of Clinical Medicine 14, no. 15: 5584. https://doi.org/10.3390/jcm14155584
APA StyleMcClain, J., Capo, G., Terris, M., Santamaria, P., & Rolle, N. A. (2025). Prevalence and Phenotype of Lower Urinary Tract Symptoms in Fibromyalgia: A Retrospective Observational Study at a Single Tertiary Medical Center. Journal of Clinical Medicine, 14(15), 5584. https://doi.org/10.3390/jcm14155584